ReviewBritish journal of pharmacology2014
Therapeutic interventions in sepsis: current and anticipated pharmacological agents.
Review in British journal of pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 69 citations in OpenAlex.
- Microglial Activation Plays a Critical Role in LPS-Induced Contextual Fear Memory Consolidation Impairment and Blood-Brain Barrier Disruption.Brain and behavior · 2026Article
- Endothelial cell responses in sepsis are attenuated by targeting truncated procalcitonin.Nature communications · 2026Article
- Obesity and Depression.Advances in experimental medicine and biology · 2026Review
- Multi‑omics reveal neutrophil heterogeneity in sepsis (Review).International journal of molecular medicine · 2025Review
- Montelukast treatsMicrobiology spectrum · 2025Article
- Bug Wars: Artificial Intelligence Strikes Back in Sepsis Management.Diagnostics (Basel, Switzerland) · 2025Review
- Novel Therapies for Right Ventricular Failure.Current cardiology reports · 2025Review
- CD5L as a promising biological therapeutic for treating sepsis.Nature communications · 2024Article
- Applications of peptides in nanosystems for diagnosing and managing bacterial sepsis.Journal of biomedical science · 2024Review
- Inflammaging in Multidrug-Resistant Sepsis of Geriatric ICU Patients and Healthcare Challenges.Geriatrics (Basel, Switzerland) · 2024Review
- A gene network database for the identification of key genes for diagnosis, prognosis, and treatment in sepsis.Scientific reports · 2023Article
- Treatment Advances in Sepsis and Septic Shock: Modulating Pro- and Anti-Inflammatory Mechanisms.Journal of clinical medicine · 2023Review
- The Relationship between Stress, Inflammation, and Depression.Biomedicines · 2022Review
- Anisomycin protects against sepsis by attenuating IκB kinase-dependent NF-κB activation and inflammatory gene expression.BMB reports · 2021Article
- Ramelteon Ameliorates LPS-Induced Hyperpermeability of the Blood-Brain Barrier (BBB) by Activating Nrf2.Inflammation · 2021Article
- Isoflurane reduces septic neuron injury by HO‑1‑mediated abatement of inflammation and apoptosis.Molecular medicine reports · 2021Article
- Immune suppression reversal of the spleen: a promising strategy for improving the survival rate of sepsis in rats.American journal of translational research · 2021Article
- Specialized proresolving mediators in infection and lung injury.BioFactors (Oxford, England) · 2021Review
- Applications of Nanobiomaterials in the Therapy and Imaging of Acute Liver Failure.Nano-micro letters · 2020Review
- Linkage of lncRNA CRNDE sponging miR-181a-5p with aggravated inflammation underlying sepsis.Innate immunity · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a clinical syndrome characterized by a multisystem response to a pathogenic assault due to underlying infection that involves a combination of interconnected biochemical, cellular and organ-organ interactive networks. After the withdrawal of recombinant human-activated protein C (rAPC), researchers and physicians have continued to search for new therapeutic approaches and targets against sepsis, effective in both hypo- and hyperinflammatory states. Currently, statins are being evaluated as a viable option in clinical trials. Many agents that have shown favourable results in experimental sepsis are not clinically effective or have not been clinically evaluated. Apart from developing new therapeutic molecules, there is great scope for for developing a variety of drug delivery strategies, such as nanoparticulate carriers and phospholipid-based systems. These nanoparticulate carriers neutralize intracorporeal LPS as well as deliver therapeutic agents to targeted tissues and subcellular locations. Here, we review and critically discuss the present status and new experimental and clinical approaches for therapeutic intervention in sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.